ID   ACVL1_HUMAN             Reviewed;         503 AA.
AC   P37023; A6NGA8;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   15-DEC-1998, sequence version 2.
DT   12-OCT-2022, entry version 229.
DE   RecName: Full=Serine/threonine-protein kinase receptor R3;
DE            Short=SKR3;
DE            EC=2.7.11.30;
DE   AltName: Full=Activin receptor-like kinase 1;
DE            Short=ALK-1;
DE   AltName: Full=TGF-B superfamily receptor type I;
DE            Short=TSR-I;
DE   Flags: Precursor;
GN   Name=ACVRL1; Synonyms=ACVRLK1, ALK1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Placenta;
RX   PubMed=8397373;
RA   ten Dijke P., Ichijo H., Franzen P., Schulz P., Saras J., Toyoshima H.,
RA   Heldin C.-H., Miyazono K.;
RT   "Activin receptor-like kinases: a novel subclass of cell-surface receptors
RT   with predicted serine/threonine kinase activity.";
RL   Oncogene 8:2879-2887(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=8242742; DOI=10.1016/0092-8674(93)90488-c;
RA   Attisano L., Carcamo J., Ventura F., Weis F.M., Massague J., Wrana J.L.;
RT   "Identification of human activin and TGF beta type I receptors that form
RT   heteromeric kinase complexes with type II receptors.";
RL   Cell 75:671-680(1993).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS HHT2 CYS-50; GLN-67;
RP   ILE-333; TRP-374 AND THR-424.
RX   PubMed=9245985; DOI=10.1086/513903;
RA   Berg J.N., Gallione C.J., Stenzel T.T., Johnson D.W., Allen W.P.,
RA   Schwartz C.E., Jackson C.E., Porteous M.E.M., Marchuk D.A.;
RT   "The activin receptor-like kinase 1 gene: genomic structure and mutations
RT   in hereditary hemorrhagic telangiectasia type 2.";
RL   Am. J. Hum. Genet. 61:60-67(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M., Kovar-Smith C.,
RA   Lewis L.R., Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R.,
RA   Montgomery K.T., Morgan M.B., Nazareth L.V., Scott G., Sodergren E.,
RA   Song X.-Z., Steffen D., Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y.,
RA   Zhang Z., Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G.,
RA   Chen Z., Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H.,
RA   Draper H., Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S.,
RA   Kelly S.H., Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M.,
RA   Nguyen B.-V., Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H.,
RA   Santibanez J., Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q.,
RA   Williams G.A., Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V.,
RA   Bailey M., Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E.,
RA   Burkett C.E., Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M., Dathorne S.R.,
RA   David R., Davis C.M., Davy-Carroll L., Deshazo D.R., Donlin J.E.,
RA   D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J., Escotto M., Flagg N.,
RA   Forbes L.D., Gabisi A.M., Garza M., Hamilton C., Henderson N.,
RA   Hernandez O., Hines S., Hogues M.E., Huang M., Idlebird D.G., Johnson R.,
RA   Jolivet A., Jones S., Kagan R., King L.M., Leal B., Lebow H., Lee S.,
RA   LeVan J.M., Lewis L.C., London P., Lorensuhewa L.M., Loulseged H.,
RA   Lovett D.A., Lucier A., Lucier R.L., Ma J., Madu R.C., Mapua P.,
RA   Martindale A.D., Martinez E., Massey E., Mawhiney S., Meador M.G.,
RA   Mendez S., Mercado C., Mercado I.C., Merritt C.E., Miner Z.L., Minja E.,
RA   Mitchell T., Mohabbat F., Mohabbat K., Montgomery B., Moore N., Morris S.,
RA   Munidasa M., Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O.,
RA   Nwokenkwo S., Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D., Trejos Z.Y.,
RA   Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I., Vera V.A.,
RA   Villasana D.M., Wang L., Ward-Moore S., Warren J.T., Wei X., White F.,
RA   Williamson A.L., Wleczyk R., Wooden H.S., Wooden S.H., Yen J., Yoon L.,
RA   Yoon V., Zorrilla S.E., Nelson D., Kucherlapati R., Weinstock G.,
RA   Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   STRUCTURE BY NMR OF 19-118, FUNCTION AS BMP9 RECEPTOR, DISULFIDE BONDS, AND
RP   MUTAGENESIS OF 74-ARG--LEU-76.
RX   PubMed=22799562; DOI=10.1021/bi300942x;
RA   Mahlawat P., Ilangovan U., Biswas T., Sun L.Z., Hinck A.P.;
RT   "Structure of the Alk1 extracellular domain and characterization of its
RT   bone morphogenetic protein (BMP) binding properties.";
RL   Biochemistry 51:6328-6341(2012).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (3.36 ANGSTROMS) OF 22-118 IN COMPLEX WITH BMP9 AND
RP   ACVR2B, FUNCTION AS BMP9 AND BMP10 RECEPTOR, AND DISULFIDE BONDS.
RX   PubMed=22718755; DOI=10.1074/jbc.m112.377960;
RA   Townson S.A., Martinez-Hackert E., Greppi C., Lowden P., Sako D., Liu J.,
RA   Ucran J.A., Liharska K., Underwood K.W., Seehra J., Kumar R.,
RA   Grinberg A.V.;
RT   "Specificity and structure of a high affinity activin receptor-like kinase
RT   1 (ALK1) signaling complex.";
RL   J. Biol. Chem. 287:27313-27325(2012).
RN   [9]
RP   VARIANTS HHT2 SER-232 DEL; ARG-376 AND GLN-411.
RX   PubMed=8640225; DOI=10.1038/ng0696-189;
RA   Johnson D.W., Berg J.N., Baldwin M.A., Gallione C.J., Marondel I.,
RA   Yoon S.-J., Stenzel T.T., Speer M., Pericak-Vance M.A., Diamond A.,
RA   Guttmacher A.E., Jackson C.E., Attisano L., Kucherlapati R.,
RA   Porteous M.E.M., Marchuk D.A.;
RT   "Mutations in the activin receptor-like kinase 1 gene in hereditary
RT   haemorrhagic telangiectasia type 2.";
RL   Nat. Genet. 13:189-194(1996).
RN   [10]
RP   VARIANTS HHT2 TYR-51; TRP-77 AND ASP-96.
RX   PubMed=10694922;
RA   Klaus D.J., Gallione C.J., Anthony K., Yeh E.Y., Yu J., Lux A.,
RA   Johnson D.W., Marchuk D.A.;
RT   "Novel missense and frameshift mutations in the activin receptor-like
RT   kinase-1 gene in hereditary hemorrhagic telangiectasia.";
RL   Hum. Mutat. 12:137-137(1998).
RN   [11]
RP   VARIANTS HHT2 GLY-48-49-ALA DELINS EP; CYS-50; SER-232 DEL; ILE-333;
RP   TYR-344 AND ASP-407.
RX   PubMed=10767348; DOI=10.1093/hmg/9.8.1227;
RA   Abdalla S.A., Pece-Barbara N., Vera S., Tapia E., Paez E., Bernabeu C.,
RA   Letarte M.;
RT   "Analysis of ALK-1 and endoglin in newborns from families with hereditary
RT   hemorrhagic telangiectasia type 2.";
RL   Hum. Mol. Genet. 9:1227-1237(2000).
RN   [12]
RP   VARIANTS HHT2 TRP-374 AND ASN-398.
RX   PubMed=11170071;
RX   DOI=10.1002/1096-8628(20010201)98:4<298::aid-ajmg1093>3.0.co;2-k;
RA   Kjeldsen A.D., Brusgaard K., Poulsen L., Kruse T., Rasmussen K., Green A.,
RA   Vase P.;
RT   "Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic
RT   telangiectasia in two large Danish families.";
RL   Am. J. Med. Genet. 98:298-302(2001).
RN   [13]
RP   VARIANTS HHT2 ASP-254 DEL; TRP-411 AND TRP-484.
RX   PubMed=11484689; DOI=10.1056/nejm200108023450503;
RA   Trembath R.C., Thomson J.R., Machado R.D., Morgan N.V., Atkinson C.,
RA   Winship I., Simonneau G., Galie N., Loyd J.E., Humbert M., Nichols W.C.,
RA   Berg J., Manes A., McGaughran J., Pauciulo M., Wheeler L., Morrell N.W.;
RT   "Clinical and molecular genetic features of pulmonary hypertension in
RT   patients with hereditary hemorrhagic telangiectasia.";
RL   N. Engl. J. Med. 345:325-334(2001).
RN   [14]
RP   VARIANTS HHT2 ALA-179; ASP-211; TYR-344; TRP-374; GLN-374; SER-399; GLN-411
RP   AND THR-487, AND CHARACTERIZATION OF VARIANTS HHT2 CYS-50; GLN-67; TRP-77;
RP   ALA-179; ASP-211; SER-232 DEL; ASP-254 DEL; ILE-333; TYR-344; GLN-374;
RP   LEU-378; GLN-411 AND THR-487.
RX   PubMed=14684682; DOI=10.1136/jmg.40.12.865;
RA   Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J.,
RA   Machado R.D., Elliott C.G., Robbins I.M., Olschewski H., McLaughlin V.,
RA   Gruenig E., Kermeen F., Halme M., Raeisaenen-Sokolowski A., Laitinen T.,
RA   Morrell N.W., Trembath R.C.;
RT   "Molecular and functional analysis identifies ALK-1 as the predominant
RT   cause of pulmonary hypertension related to hereditary haemorrhagic
RT   telangiectasia.";
RL   J. Med. Genet. 40:865-871(2003).
RN   [15]
RP   ERRATUM OF PUBMED:14684682.
RA   Harrison R.E., Flanagan J.A., Sankelo M., Abdalla S.A., Rowell J.,
RA   Machado R.D., Elliott C.G., Robbins I.M., Olschewski H., McLaughlin V.,
RA   Gruenig E., Kermeen F., Halme M., Raeisaenen-Sokolowski A., Laitinen T.,
RA   Morrell N.W., Trembath R.C.;
RL   J. Med. Genet. 41:576-576(2004).
RN   [16]
RP   VARIANTS HHT2 ARG-48; LYS-215; ARG-223; ARG-229; SER-233 DEL; PHE-285;
RP   PRO-306; TYR-314; PRO-337; PRO-347; GLN-374; VAL-376; LYS-379; GLY-397;
RP   TRP-411; PRO-411; GLN-411; LEU-425; LEU-479; VAL-482 AND TRP-484.
RX   PubMed=15024723; DOI=10.1002/humu.20017;
RG   French Rendu-Osler network;
RA   Lesca G., Plauchu H., Coulet F., Lefebvre S., Plessis G., Odent S.,
RA   Riviere S., Leheup B., Goizet C., Carette M.-F., Cordier J.-F., Pinson S.,
RA   Soubrier F., Calender A., Giraud S.;
RT   "Molecular screening of ALK1/ACVRL1 and ENG genes in hereditary hemorrhagic
RT   telangiectasia in France.";
RL   Hum. Mutat. 23:289-299(2004).
RN   [17]
RP   VARIANTS HHT2 TRP-67; TRP-374; LYS-379; ASP-407; TRP-411; VAL-425 AND
RP   PHE-425 DEL.
RX   PubMed=15712270; DOI=10.1002/humu.9311;
RA   Kuehl H.K.A., Caselitz M., Hasenkamp S., Wagner S., El-Harith E.-H.A.,
RA   Manns M.P., Stuhrmann M.;
RT   "Hepatic manifestation is associated with ALK1 in hereditary hemorrhagic
RT   telangiectasia: identification of five novel ALK1 and one novel ENG
RT   mutations.";
RL   Hum. Mutat. 25:320-320(2005).
RN   [18]
RP   VARIANT SER-30, AND VARIANTS HHT2 TYR-34; ALA-52; ILE-197; ASP-219;
RP   LYS-237; LEU-260; PRO-289; ARG-344; CYS-426 AND ARG-433.
RX   PubMed=16752392; DOI=10.1002/humu.20342;
RA   Bossler A.D., Richards J., George C., Godmilow L., Ganguly A.;
RT   "Novel mutations in ENG and ACVRL1 identified in a series of 200
RT   individuals undergoing clinical genetic testing for hereditary hemorrhagic
RT   telangiectasia (HHT): correlation of genotype with phenotype.";
RL   Hum. Mutat. 27:667-675(2006).
RN   [19]
RP   VARIANTS HHT2 GLY-50; PRO-66; ARG-69; TYR-176; LEU-233; PRO-265; PRO-403
RP   AND SER-416.
RX   PubMed=16525724;
RA   Argyriou L., Twelkemeyer S., Panchulidze I., Wehner L.E., Teske U.,
RA   Engel W., Nayernia K.;
RT   "Novel mutations in the ENG and ACVRL1 genes causing hereditary hemorrhagic
RT   teleangiectasia.";
RL   Int. J. Mol. Med. 17:655-659(2006).
RN   [20]
RP   VARIANTS CYS-38; PRO-138; LYS-277; PRO-342; THR-400 AND GLU-486, AND
RP   VARIANTS HHT2 SER-96; GLY-217; GLU-226; ARG-280; ARG-294; GLN-328; HIS-335;
RP   ASP-347; SER-378; ARG-424; SER-449 AND PRO-479.
RX   PubMed=20414677; DOI=10.1007/s00439-010-0825-4;
RA   Richards-Yutz J., Grant K., Chao E.C., Walther S.E., Ganguly A.;
RT   "Update on molecular diagnosis of hereditary hemorrhagic telangiectasia.";
RL   Hum. Genet. 128:61-77(2010).
RN   [21]
RP   VARIANTS ASN-8; VAL-59; VAL-159; CYS-225 AND ALA-396.
RX   PubMed=24936649; DOI=10.1371/journal.pone.0100261;
RA   Pousada G., Baloira A., Vilarino C., Cifrian J.M., Valverde D.;
RT   "Novel mutations in BMPR2, ACVRL1 and KCNA5 genes and hemodynamic
RT   parameters in patients with pulmonary arterial hypertension.";
RL   PLoS ONE 9:E100261-E100261(2014).
RN   [22]
RP   VARIANTS HHT2 GLY-41; TYR-41; GLY-46; PRO-47; TYR-66; PHE-77; ASP-211;
RP   SER-211; VAL-245; PRO-306; VAL-313; TYR-314; SER-378; ASP-379; LYS-379;
RP   GLY-404; TRP-411; MET-441 AND TYR-443, VARIANTS ASP-111 AND PHE-417,
RP   CHARACTERIZATION OF VARIANTS HHT2 GLY-41; TYR-41; GLY-46; PRO-47; TYR-66;
RP   PHE-77; ASP-211; SER-211; VAL-245; PRO-306; VAL-313; TYR-314; SER-378;
RP   ASP-379; LYS-379; GLY-404; TRP-411; MET-441 AND TYR-443, CHARACTERIZATION
RP   OF VARIANTS ASP-111 AND PHE-417, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=26176610; DOI=10.1371/journal.pone.0132111;
RA   Alaa El Din F., Patri S., Thoreau V., Rodriguez-Ballesteros M., Hamade E.,
RA   Bailly S., Gilbert-Dussardier B., Abou Merhi R., Kitzis A.;
RT   "Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort
RT   of patients affected by hereditary hemorrhagic telangiectasia.";
RL   PLoS ONE 10:E0132111-E0132111(2015).
CC   -!- FUNCTION: Type I receptor for TGF-beta family ligands BMP9/GDF2 and
CC       BMP10 and important regulator of normal blood vessel development. On
CC       ligand binding, forms a receptor complex consisting of two type II and
CC       two type I transmembrane serine/threonine kinases. Type II receptors
CC       phosphorylate and activate type I receptors which autophosphorylate,
CC       then bind and activate SMAD transcriptional regulators. May bind
CC       activin as well. {ECO:0000269|PubMed:22718755,
CC       ECO:0000269|PubMed:22799562, ECO:0000269|PubMed:26176610}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[receptor-protein] = ADP + H(+) + O-phospho-
CC         L-threonyl-[receptor-protein]; Xref=Rhea:RHEA:44880, Rhea:RHEA-
CC         COMP:11024, Rhea:RHEA-COMP:11025, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:30013, ChEBI:CHEBI:30616, ChEBI:CHEBI:61977,
CC         ChEBI:CHEBI:456216; EC=2.7.11.30;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[receptor-protein] = ADP + H(+) + O-phospho-L-
CC         seryl-[receptor-protein]; Xref=Rhea:RHEA:18673, Rhea:RHEA-COMP:11022,
CC         Rhea:RHEA-COMP:11023, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:83421, ChEBI:CHEBI:456216;
CC         EC=2.7.11.30;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035; Evidence={ECO:0000250};
CC   -!- INTERACTION:
CC       P37023; PRO_0000033903 [Q9UK05]: GDF2; NbExp=2; IntAct=EBI-8043559, EBI-16227344;
CC       P37023; P02750: LRG1; NbExp=3; IntAct=EBI-8043559, EBI-9083443;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:26176610};
CC       Single-pass type I membrane protein {ECO:0000255}.
CC   -!- DISEASE: Telangiectasia, hereditary hemorrhagic, 2 (HHT2) [MIM:600376]:
CC       A multisystemic vascular dysplasia leading to dilation of permanent
CC       blood vessels and arteriovenous malformations of skin, mucosa, and
CC       viscera. The disease is characterized by recurrent epistaxis and
CC       gastro-intestinal hemorrhage. Visceral involvement includes
CC       arteriovenous malformations of the lung, liver, and brain.
CC       {ECO:0000269|PubMed:10694922, ECO:0000269|PubMed:10767348,
CC       ECO:0000269|PubMed:11170071, ECO:0000269|PubMed:11484689,
CC       ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:15024723,
CC       ECO:0000269|PubMed:15712270, ECO:0000269|PubMed:16525724,
CC       ECO:0000269|PubMed:16752392, ECO:0000269|PubMed:20414677,
CC       ECO:0000269|PubMed:26176610, ECO:0000269|PubMed:8640225,
CC       ECO:0000269|PubMed:9245985}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. TKL Ser/Thr
CC       protein kinase family. TGFB receptor subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Hereditary Hemorrhagic Telangiectasia and ENG;
CC       URL="http://arup.utah.edu/database/ACVRL1/ACVRL1_welcome.php";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z22533; CAA80255.1; -; mRNA.
DR   EMBL; L17075; AAA16160.1; -; mRNA.
DR   EMBL; U77713; AAB61900.1; -; Genomic_DNA.
DR   EMBL; U77707; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77708; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77709; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77710; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77711; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; U77712; AAB61900.1; JOINED; Genomic_DNA.
DR   EMBL; AC025259; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471111; EAW58213.1; -; Genomic_DNA.
DR   EMBL; BC042637; AAH42637.1; -; mRNA.
DR   CCDS; CCDS31804.1; -.
DR   PIR; A49431; A49431.
DR   RefSeq; NP_000011.2; NM_000020.2.
DR   RefSeq; NP_001070869.1; NM_001077401.1.
DR   RefSeq; XP_005269292.1; XM_005269235.2.
DR   PDB; 2LCR; NMR; -; A=22-118.
DR   PDB; 3MY0; X-ray; 2.65 A; A/B/C/D/E/F/G/H/I/J/K/L/M/N/O/P/Q/R/S/T/U/V/W/X=195-497.
DR   PDB; 4FAO; X-ray; 3.36 A; C/D/I/J/O/P/U/V/c/d/i/j=22-118.
DR   PDB; 6SF1; X-ray; 2.80 A; A=21-118.
DR   PDB; 6SF2; X-ray; 3.30 A; A/D=21-118.
DR   PDB; 6SF3; X-ray; 2.30 A; A=21-118.
DR   PDBsum; 2LCR; -.
DR   PDBsum; 3MY0; -.
DR   PDBsum; 4FAO; -.
DR   PDBsum; 6SF1; -.
DR   PDBsum; 6SF2; -.
DR   PDBsum; 6SF3; -.
DR   AlphaFoldDB; P37023; -.
DR   BMRB; P37023; -.
DR   SMR; P37023; -.
DR   BioGRID; 106609; 32.
DR   DIP; DIP-5938N; -.
DR   IntAct; P37023; 8.
DR   MINT; P37023; -.
DR   STRING; 9606.ENSP00000373574; -.
DR   BindingDB; P37023; -.
DR   ChEMBL; CHEMBL5311; -.
DR   DrugBank; DB00171; ATP.
DR   DrugCentral; P37023; -.
DR   GuidetoPHARMACOLOGY; 1784; -.
DR   GlyGen; P37023; 1 site.
DR   iPTMnet; P37023; -.
DR   PhosphoSitePlus; P37023; -.
DR   BioMuta; ACVRL1; -.
DR   DMDM; 3915750; -.
DR   EPD; P37023; -.
DR   jPOST; P37023; -.
DR   MassIVE; P37023; -.
DR   PaxDb; P37023; -.
DR   PeptideAtlas; P37023; -.
DR   PRIDE; P37023; -.
DR   ProteomicsDB; 55254; -.
DR   ABCD; P37023; 1 sequenced antibody.
DR   Antibodypedia; 2055; 640 antibodies from 40 providers.
DR   DNASU; 94; -.
DR   Ensembl; ENST00000388922.9; ENSP00000373574.4; ENSG00000139567.13.
DR   GeneID; 94; -.
DR   KEGG; hsa:94; -.
DR   MANE-Select; ENST00000388922.9; ENSP00000373574.4; NM_000020.3; NP_000011.2.
DR   UCSC; uc001rzj.4; human.
DR   CTD; 94; -.
DR   DisGeNET; 94; -.
DR   GeneCards; ACVRL1; -.
DR   GeneReviews; ACVRL1; -.
DR   HGNC; HGNC:175; ACVRL1.
DR   HPA; ENSG00000139567; Tissue enhanced (lung).
DR   MalaCards; ACVRL1; -.
DR   MIM; 600376; phenotype.
DR   MIM; 601284; gene.
DR   neXtProt; NX_P37023; -.
DR   OpenTargets; ENSG00000139567; -.
DR   Orphanet; 774; Hereditary hemorrhagic telangiectasia.
DR   Orphanet; 275777; Heritable pulmonary arterial hypertension.
DR   PharmGKB; PA24496; -.
DR   VEuPathDB; HostDB:ENSG00000139567; -.
DR   eggNOG; KOG2052; Eukaryota.
DR   GeneTree; ENSGT00940000161446; -.
DR   HOGENOM; CLU_000288_8_1_1; -.
DR   InParanoid; P37023; -.
DR   OMA; CQGTWCT; -.
DR   OrthoDB; 776697at2759; -.
DR   PhylomeDB; P37023; -.
DR   TreeFam; TF314724; -.
DR   BRENDA; 2.7.10.2; 2681.
DR   BRENDA; 2.7.11.30; 2681.
DR   PathwayCommons; P37023; -.
DR   Reactome; R-HSA-201451; Signaling by BMP.
DR   SignaLink; P37023; -.
DR   SIGNOR; P37023; -.
DR   BioGRID-ORCS; 94; 20 hits in 1108 CRISPR screens.
DR   ChiTaRS; ACVRL1; human.
DR   GeneWiki; ACVRL1; -.
DR   GenomeRNAi; 94; -.
DR   Pharos; P37023; Tchem.
DR   PRO; PR:P37023; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   RNAct; P37023; protein.
DR   Bgee; ENSG00000139567; Expressed in right lung and 150 other tissues.
DR   ExpressionAtlas; P37023; baseline and differential.
DR   Genevisible; P37023; HS.
DR   GO; GO:0070724; C:BMP receptor complex; IBA:GO_Central.
DR   GO; GO:0009986; C:cell surface; IDA:MGI.
DR   GO; GO:0030425; C:dendrite; IEA:Ensembl.
DR   GO; GO:0005887; C:integral component of plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IBA:GO_Central.
DR   GO; GO:0048185; F:activin binding; IDA:UniProtKB.
DR   GO; GO:0016361; F:activin receptor activity, type I; IDA:MGI.
DR   GO; GO:0005524; F:ATP binding; IDA:HGNC-UCL.
DR   GO; GO:0098821; F:BMP receptor activity; IMP:UniProtKB.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:HGNC-UCL.
DR   GO; GO:0046332; F:SMAD binding; IDA:HGNC-UCL.
DR   GO; GO:0050431; F:transforming growth factor beta binding; IPI:UniProtKB.
DR   GO; GO:0005024; F:transforming growth factor beta receptor activity; IDA:MGI.
DR   GO; GO:0005025; F:transforming growth factor beta receptor activity, type I; IDA:UniProtKB.
DR   GO; GO:0004675; F:transmembrane receptor protein serine/threonine kinase activity; NAS:UniProtKB.
DR   GO; GO:0001525; P:angiogenesis; IMP:HGNC-UCL.
DR   GO; GO:0060840; P:artery development; ISS:BHF-UCL.
DR   GO; GO:0008015; P:blood circulation; IMP:HGNC-UCL.
DR   GO; GO:0002043; P:blood vessel endothelial cell proliferation involved in sprouting angiogenesis; TAS:DFLAT.
DR   GO; GO:0001955; P:blood vessel maturation; TAS:DFLAT.
DR   GO; GO:0001974; P:blood vessel remodeling; ISS:BHF-UCL.
DR   GO; GO:0030509; P:BMP signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0071773; P:cellular response to BMP stimulus; IMP:BHF-UCL.
DR   GO; GO:0071363; P:cellular response to growth factor stimulus; IBA:GO_Central.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IDA:BHF-UCL.
DR   GO; GO:0035912; P:dorsal aorta morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0009953; P:dorsal/ventral pattern formation; IBA:GO_Central.
DR   GO; GO:0003203; P:endocardial cushion morphogenesis; ISS:BHF-UCL.
DR   GO; GO:0061154; P:endothelial tube morphogenesis; IMP:BHF-UCL.
DR   GO; GO:0007507; P:heart development; IBA:GO_Central.
DR   GO; GO:0001701; P:in utero embryonic development; IEA:Ensembl.
DR   GO; GO:0001946; P:lymphangiogenesis; ISS:BHF-UCL.
DR   GO; GO:0060836; P:lymphatic endothelial cell differentiation; IMP:BHF-UCL.
DR   GO; GO:0043537; P:negative regulation of blood vessel endothelial cell migration; IMP:BHF-UCL.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IMP:HGNC-UCL.
DR   GO; GO:0030308; P:negative regulation of cell growth; IDA:BHF-UCL.
DR   GO; GO:0030336; P:negative regulation of cell migration; IMP:HGNC-UCL.
DR   GO; GO:0008285; P:negative regulation of cell population proliferation; IMP:HGNC-UCL.
DR   GO; GO:2000279; P:negative regulation of DNA biosynthetic process; IMP:BHF-UCL.
DR   GO; GO:0045602; P:negative regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0010596; P:negative regulation of endothelial cell migration; IDA:BHF-UCL.
DR   GO; GO:0001937; P:negative regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0051895; P:negative regulation of focal adhesion assembly; IMP:HGNC-UCL.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISS:BHF-UCL.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IEA:Ensembl.
DR   GO; GO:0030513; P:positive regulation of BMP signaling pathway; IDA:BHF-UCL.
DR   GO; GO:0032332; P:positive regulation of chondrocyte differentiation; TAS:BHF-UCL.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IDA:HGNC-UCL.
DR   GO; GO:0045603; P:positive regulation of endothelial cell differentiation; IEA:Ensembl.
DR   GO; GO:0001938; P:positive regulation of endothelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010862; P:positive regulation of pathway-restricted SMAD protein phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:HGNC-UCL.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:HGNC-UCL.
DR   GO; GO:0043535; P:regulation of blood vessel endothelial cell migration; TAS:DFLAT.
DR   GO; GO:0006275; P:regulation of DNA replication; TAS:DFLAT.
DR   GO; GO:0006355; P:regulation of DNA-templated transcription; IMP:HGNC-UCL.
DR   GO; GO:0001936; P:regulation of endothelial cell proliferation; TAS:DFLAT.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0061298; P:retina vasculature development in camera-type eye; ISS:BHF-UCL.
DR   GO; GO:0007165; P:signal transduction; IDA:HGNC-UCL.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; IDA:HGNC-UCL.
DR   GO; GO:0060841; P:venous blood vessel development; ISS:BHF-UCL.
DR   GO; GO:0035313; P:wound healing, spreading of epidermal cells; IMP:HGNC-UCL.
DR   Gene3D; 2.10.60.10; -; 1.
DR   InterPro; IPR003605; GS_dom.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR045860; Snake_toxin-like_sf.
DR   InterPro; IPR000333; TGFB_receptor.
DR   PANTHER; PTHR23255; PTHR23255; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF08515; TGF_beta_GS; 1.
DR   PRINTS; PR00653; ACTIVIN2R.
DR   SMART; SM00467; GS; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57302; SSF57302; 1.
DR   PROSITE; PS51256; GS; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Angiogenesis; ATP-binding; Cell membrane; Disease variant;
KW   Disulfide bond; Glycoprotein; Kinase; Magnesium; Manganese; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Receptor;
KW   Reference proteome; Serine/threonine-protein kinase; Signal; Transferase;
KW   Transmembrane; Transmembrane helix.
FT   SIGNAL          1..21
FT                   /evidence="ECO:0000255"
FT   CHAIN           22..503
FT                   /note="Serine/threonine-protein kinase receptor R3"
FT                   /id="PRO_0000024420"
FT   TOPO_DOM        22..118
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        119..141
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        142..503
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          172..201
FT                   /note="GS"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00585"
FT   DOMAIN          202..492
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          73..76
FT                   /note="Mediates specificity for BMP ligand"
FT   ACT_SITE        330
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10027"
FT   BINDING         208..216
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         229
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         155
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61288"
FT   MOD_RES         160
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61288"
FT   MOD_RES         161
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q61288"
FT   CARBOHYD        98
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        34..51
FT                   /evidence="ECO:0000269|PubMed:22718755,
FT                   ECO:0000269|PubMed:22799562, ECO:0007744|PDB:2LCR,
FT                   ECO:0007744|PDB:4FAO"
FT   DISULFID        36..41
FT                   /evidence="ECO:0000269|PubMed:22718755,
FT                   ECO:0000269|PubMed:22799562, ECO:0007744|PDB:2LCR,
FT                   ECO:0007744|PDB:4FAO"
FT   DISULFID        46..69
FT                   /evidence="ECO:0000269|PubMed:22718755,
FT                   ECO:0000269|PubMed:22799562, ECO:0007744|PDB:2LCR,
FT                   ECO:0007744|PDB:4FAO"
FT   DISULFID        77..89
FT                   /evidence="ECO:0000269|PubMed:22718755,
FT                   ECO:0000269|PubMed:22799562, ECO:0007744|PDB:2LCR,
FT                   ECO:0007744|PDB:4FAO"
FT   DISULFID        90..95
FT                   /evidence="ECO:0000269|PubMed:22718755,
FT                   ECO:0000269|PubMed:22799562, ECO:0007744|PDB:2LCR,
FT                   ECO:0007744|PDB:4FAO"
FT   VARIANT         8
FT                   /note="K -> N"
FT                   /evidence="ECO:0000269|PubMed:24936649"
FT                   /id="VAR_079583"
FT   VARIANT         30
FT                   /note="P -> S (found in a patient with hereditary
FT                   hemorrhagic talagiectasia; unknown pathological
FT                   significance; dbSNP:rs149664056)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070308"
FT   VARIANT         34
FT                   /note="C -> Y (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070309"
FT   VARIANT         38
FT                   /note="S -> C"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070310"
FT   VARIANT         41
FT                   /note="C -> G (in HHT2; loss of receptor activity in
FT                   response to BMP9; predominantly retained in the endoplasmic
FT                   reticulum)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075231"
FT   VARIANT         41
FT                   /note="C -> Y (in HHT2; loss of receptor activity in
FT                   response to BMP9; predominantly retained in the endoplasmic
FT                   reticulum; dbSNP:rs1184716348)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075232"
FT   VARIANT         46
FT                   /note="C -> G (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075233"
FT   VARIANT         47
FT                   /note="R -> P (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum;
FT                   dbSNP:rs774389618)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075234"
FT   VARIANT         48..49
FT                   /note="GA -> EP (in HHT2; dbSNP:rs387906392)"
FT                   /id="VAR_026784"
FT   VARIANT         48
FT                   /note="G -> R (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026785"
FT   VARIANT         50
FT                   /note="W -> C (in HHT2; retained in the endoplasmic
FT                   reticulum; dbSNP:rs121909285)"
FT                   /evidence="ECO:0000269|PubMed:10767348,
FT                   ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:9245985"
FT                   /id="VAR_006204"
FT   VARIANT         50
FT                   /note="W -> G (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16525724"
FT                   /id="VAR_070311"
FT   VARIANT         51
FT                   /note="C -> Y (in HHT2; dbSNP:rs863223409)"
FT                   /evidence="ECO:0000269|PubMed:10694922"
FT                   /id="VAR_006205"
FT   VARIANT         52
FT                   /note="T -> A (in HHT2; dbSNP:rs1131691346)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070312"
FT   VARIANT         59
FT                   /note="E -> V (found in a patient with pulmonary arterial
FT                   hypertension; unknown pathological significance;
FT                   dbSNP:rs1466116430)"
FT                   /evidence="ECO:0000269|PubMed:24936649"
FT                   /id="VAR_079584"
FT   VARIANT         66
FT                   /note="H -> P (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16525724"
FT                   /id="VAR_070313"
FT   VARIANT         66
FT                   /note="H -> Y (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum;
FT                   dbSNP:rs1480110873)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075235"
FT   VARIANT         67
FT                   /note="R -> Q (in HHT2; retained in the endoplasmic
FT                   reticulum; dbSNP:rs863223414)"
FT                   /evidence="ECO:0000269|PubMed:14684682,
FT                   ECO:0000269|PubMed:9245985"
FT                   /id="VAR_006206"
FT   VARIANT         67
FT                   /note="R -> W (in HHT2; dbSNP:rs1085307405)"
FT                   /evidence="ECO:0000269|PubMed:15712270"
FT                   /id="VAR_026786"
FT   VARIANT         69
FT                   /note="C -> R (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16525724"
FT                   /id="VAR_070314"
FT   VARIANT         77
FT                   /note="C -> F (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum;
FT                   dbSNP:rs1330837892)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075236"
FT   VARIANT         77
FT                   /note="C -> W (in HHT2; retained in the endoplasmic
FT                   reticulum)"
FT                   /evidence="ECO:0000269|PubMed:10694922,
FT                   ECO:0000269|PubMed:14684682"
FT                   /id="VAR_006207"
FT   VARIANT         96
FT                   /note="N -> D (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:10694922"
FT                   /id="VAR_006208"
FT   VARIANT         96
FT                   /note="N -> S (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070315"
FT   VARIANT         111
FT                   /note="E -> D (no loss of receptor activity in response to
FT                   BMP9; mutant protein is capable of targeting the cell
FT                   surface appropriately; dbSNP:rs1481094868)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075237"
FT   VARIANT         138
FT                   /note="L -> P"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070316"
FT   VARIANT         159
FT                   /note="E -> V (found in a patient with pulmonary arterial
FT                   hypertension; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:24936649"
FT                   /id="VAR_079585"
FT   VARIANT         176
FT                   /note="D -> Y (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16525724"
FT                   /id="VAR_070317"
FT   VARIANT         179
FT                   /note="D -> A (in HHT2; mutant protein is capable of
FT                   targeting the cell surface appropriately;
FT                   dbSNP:rs753792569)"
FT                   /evidence="ECO:0000269|PubMed:14684682"
FT                   /id="VAR_026787"
FT   VARIANT         197
FT                   /note="T -> I (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070318"
FT   VARIANT         211
FT                   /note="G -> D (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum;
FT                   dbSNP:rs28936687)"
FT                   /evidence="ECO:0000269|PubMed:14684682,
FT                   ECO:0000269|PubMed:26176610"
FT                   /id="VAR_026788"
FT   VARIANT         211
FT                   /note="G -> S (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075238"
FT   VARIANT         215
FT                   /note="E -> K (in HHT2; dbSNP:rs754283265)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026789"
FT   VARIANT         217
FT                   /note="W -> G (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070319"
FT   VARIANT         219
FT                   /note="G -> D (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070320"
FT   VARIANT         223
FT                   /note="G -> R (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026790"
FT   VARIANT         225
FT                   /note="S -> C (found in a patient with pulmonary arterial
FT                   hypertension; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:24936649"
FT                   /id="VAR_079586"
FT   VARIANT         226
FT                   /note="V -> E (in HHT2; dbSNP:rs1565593639)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070321"
FT   VARIANT         229
FT                   /note="K -> R (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026791"
FT   VARIANT         232
FT                   /note="Missing (in HHT2; mutant protein is capable of
FT                   targeting the cell surface appropriately)"
FT                   /evidence="ECO:0000269|PubMed:10767348,
FT                   ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:8640225"
FT                   /id="VAR_006209"
FT   VARIANT         233
FT                   /note="S -> L (in HHT2; dbSNP:rs762773076)"
FT                   /evidence="ECO:0000269|PubMed:16525724"
FT                   /id="VAR_070322"
FT   VARIANT         233
FT                   /note="Missing (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026792"
FT   VARIANT         237
FT                   /note="Q -> K (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070323"
FT   VARIANT         245
FT                   /note="I -> N (in dbSNP:rs1804508)"
FT                   /id="VAR_011717"
FT   VARIANT         245
FT                   /note="I -> V (in HHT2; no loss of receptor activity in
FT                   response to BMP9; mutant protein is capable of targeting
FT                   the cell surface appropriately; affects splicing by
FT                   inducing the creation of a new donor splice site and the
FT                   loss of the 3' end of exon 6)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075239"
FT   VARIANT         254
FT                   /note="Missing (in HHT2; retained in the endoplasmic
FT                   reticulum; dbSNP:rs387906393)"
FT                   /evidence="ECO:0000269|PubMed:11484689,
FT                   ECO:0000269|PubMed:14684682"
FT                   /id="VAR_026793"
FT   VARIANT         260
FT                   /note="I -> L (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070324"
FT   VARIANT         265
FT                   /note="T -> P (in HHT2; dbSNP:rs1592223978)"
FT                   /evidence="ECO:0000269|PubMed:16525724"
FT                   /id="VAR_070325"
FT   VARIANT         277
FT                   /note="T -> K (found in a patient with hereditary
FT                   hemorrhagic talagiectasia; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070326"
FT   VARIANT         280
FT                   /note="H -> R (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070327"
FT   VARIANT         285
FT                   /note="L -> F (in HHT2; dbSNP:rs1085307410)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026794"
FT   VARIANT         289
FT                   /note="L -> P (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070328"
FT   VARIANT         294
FT                   /note="L -> R (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070329"
FT   VARIANT         306
FT                   /note="A -> P (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum)"
FT                   /evidence="ECO:0000269|PubMed:15024723,
FT                   ECO:0000269|PubMed:26176610"
FT                   /id="VAR_026795"
FT   VARIANT         313
FT                   /note="L -> V (in HHT2; loss of receptor activity in
FT                   response to BMP9; predominantly retained in the endoplasmic
FT                   reticulum)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075240"
FT   VARIANT         314
FT                   /note="H -> Y (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum;
FT                   dbSNP:rs1565594311)"
FT                   /evidence="ECO:0000269|PubMed:15024723,
FT                   ECO:0000269|PubMed:26176610"
FT                   /id="VAR_026796"
FT   VARIANT         328
FT                   /note="H -> Q (in HHT2; dbSNP:rs1565594410)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070330"
FT   VARIANT         333
FT                   /note="S -> I (in HHT2; retained in the endoplasmic
FT                   reticulum; dbSNP:rs863223413)"
FT                   /evidence="ECO:0000269|PubMed:10767348,
FT                   ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:9245985"
FT                   /id="VAR_006210"
FT   VARIANT         335
FT                   /note="N -> H (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070331"
FT   VARIANT         337
FT                   /note="L -> P (in HHT2; dbSNP:rs1592224349)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026797"
FT   VARIANT         342
FT                   /note="L -> P (in dbSNP:rs762287966)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070332"
FT   VARIANT         344
FT                   /note="C -> R (in HHT2; dbSNP:rs1592224412)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070333"
FT   VARIANT         344
FT                   /note="C -> Y (in HHT2; retained in the endoplasmic
FT                   reticulum; dbSNP:rs28936688)"
FT                   /evidence="ECO:0000269|PubMed:10767348,
FT                   ECO:0000269|PubMed:14684682"
FT                   /id="VAR_026798"
FT   VARIANT         347
FT                   /note="A -> D (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070334"
FT   VARIANT         347
FT                   /note="A -> P (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026799"
FT   VARIANT         374
FT                   /note="R -> Q (in HHT2; retained in the endoplasmic
FT                   reticulum; dbSNP:rs1060503248)"
FT                   /evidence="ECO:0000269|PubMed:14684682,
FT                   ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026800"
FT   VARIANT         374
FT                   /note="R -> W (in HHT2; dbSNP:rs28936401)"
FT                   /evidence="ECO:0000269|PubMed:11170071,
FT                   ECO:0000269|PubMed:14684682, ECO:0000269|PubMed:15712270,
FT                   ECO:0000269|PubMed:9245985"
FT                   /id="VAR_006211"
FT   VARIANT         376
FT                   /note="M -> R (in HHT2; dbSNP:rs28936399)"
FT                   /evidence="ECO:0000269|PubMed:8640225"
FT                   /id="VAR_006212"
FT   VARIANT         376
FT                   /note="M -> V (in HHT2; dbSNP:rs1555153277)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026801"
FT   VARIANT         378
FT                   /note="P -> L (in HHT2; retained in the endoplasmic
FT                   reticulum)"
FT                   /evidence="ECO:0000269|PubMed:14684682"
FT                   /id="VAR_026802"
FT   VARIANT         378
FT                   /note="P -> S (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum;
FT                   dbSNP:rs959973779)"
FT                   /evidence="ECO:0000269|PubMed:20414677,
FT                   ECO:0000269|PubMed:26176610"
FT                   /id="VAR_070335"
FT   VARIANT         379
FT                   /note="E -> D (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075241"
FT   VARIANT         379
FT                   /note="E -> K (in HHT2; loss of receptor activity in
FT                   response to BMP9; retained in the endoplasmic reticulum;
FT                   dbSNP:rs1131691686)"
FT                   /evidence="ECO:0000269|PubMed:15024723,
FT                   ECO:0000269|PubMed:15712270, ECO:0000269|PubMed:26176610"
FT                   /id="VAR_026803"
FT   VARIANT         396
FT                   /note="T -> A (found in patients with pulmonary arterial
FT                   hypertension; unknown pathological significance)"
FT                   /evidence="ECO:0000269|PubMed:24936649"
FT                   /id="VAR_079587"
FT   VARIANT         397
FT                   /note="D -> G (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026804"
FT   VARIANT         398
FT                   /note="I -> N (in HHT2; dbSNP:rs121909286)"
FT                   /evidence="ECO:0000269|PubMed:11170071"
FT                   /id="VAR_026805"
FT   VARIANT         399
FT                   /note="W -> S (in HHT2; dbSNP:rs121909289)"
FT                   /evidence="ECO:0000269|PubMed:14684682"
FT                   /id="VAR_026806"
FT   VARIANT         400
FT                   /note="A -> T (found in a patient with hereditary
FT                   hemorrhagic talagiectasia; unknown pathological
FT                   significance)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070336"
FT   VARIANT         403
FT                   /note="L -> P (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16525724"
FT                   /id="VAR_070337"
FT   VARIANT         404
FT                   /note="V -> G (in HHT2; loss of receptor activity in
FT                   response to BMP9; predominantly retained in the endoplasmic
FT                   reticulum)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075242"
FT   VARIANT         407
FT                   /note="E -> D (in HHT2; dbSNP:rs1565595129)"
FT                   /evidence="ECO:0000269|PubMed:10767348,
FT                   ECO:0000269|PubMed:15712270"
FT                   /id="VAR_026807"
FT   VARIANT         411
FT                   /note="R -> P (in HHT2; dbSNP:rs121909284)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026808"
FT   VARIANT         411
FT                   /note="R -> Q (in HHT2; retained in the endoplasmic
FT                   reticulum; dbSNP:rs121909284)"
FT                   /evidence="ECO:0000269|PubMed:14684682,
FT                   ECO:0000269|PubMed:15024723, ECO:0000269|PubMed:8640225"
FT                   /id="VAR_006213"
FT   VARIANT         411
FT                   /note="R -> W (in HHT2; loss of receptor activity in
FT                   response to BMP9; predominantly retained in the endoplasmic
FT                   reticulum; dbSNP:rs121909287)"
FT                   /evidence="ECO:0000269|PubMed:11484689,
FT                   ECO:0000269|PubMed:15024723, ECO:0000269|PubMed:15712270,
FT                   ECO:0000269|PubMed:26176610"
FT                   /id="VAR_026809"
FT   VARIANT         416
FT                   /note="G -> S (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16525724"
FT                   /id="VAR_070338"
FT   VARIANT         417
FT                   /note="I -> F (no loss of receptor activity in response to
FT                   BMP9; mutant protein is capable of targeting the cell
FT                   surface appropriately; dbSNP:rs141653630)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075243"
FT   VARIANT         424
FT                   /note="P -> R (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070339"
FT   VARIANT         424
FT                   /note="P -> T (in HHT2; dbSNP:rs1085307419)"
FT                   /evidence="ECO:0000269|PubMed:9245985"
FT                   /id="VAR_006214"
FT   VARIANT         425
FT                   /note="F -> L (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026810"
FT   VARIANT         425
FT                   /note="F -> V (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15712270"
FT                   /id="VAR_026811"
FT   VARIANT         425
FT                   /note="Missing (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15712270"
FT                   /id="VAR_026812"
FT   VARIANT         426
FT                   /note="Y -> C (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070340"
FT   VARIANT         433
FT                   /note="P -> R (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:16752392"
FT                   /id="VAR_070341"
FT   VARIANT         441
FT                   /note="V -> M (in HHT2; retained in the endoplasmic
FT                   reticulum; dbSNP:rs1565596498)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075244"
FT   VARIANT         443
FT                   /note="C -> Y (in HHT2; retained in the endoplasmic
FT                   reticulum)"
FT                   /evidence="ECO:0000269|PubMed:26176610"
FT                   /id="VAR_075245"
FT   VARIANT         449
FT                   /note="P -> S (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070342"
FT   VARIANT         479
FT                   /note="R -> L (in HHT2)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026813"
FT   VARIANT         479
FT                   /note="R -> P (in HHT2; dbSNP:rs1085307426)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070343"
FT   VARIANT         482
FT                   /note="A -> V (in HHT2; dbSNP:rs139142865)"
FT                   /evidence="ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026814"
FT   VARIANT         484
FT                   /note="R -> W (in HHT2; dbSNP:rs121909288)"
FT                   /evidence="ECO:0000269|PubMed:11484689,
FT                   ECO:0000269|PubMed:15024723"
FT                   /id="VAR_026815"
FT   VARIANT         486
FT                   /note="K -> E (found in a patient with hereditary
FT                   hemorrhagic talagiectasia; unknown pathological
FT                   significance; dbSNP:rs113700354)"
FT                   /evidence="ECO:0000269|PubMed:20414677"
FT                   /id="VAR_070344"
FT   VARIANT         487
FT                   /note="K -> T (in HHT2; mutant protein is capable of
FT                   targeting the cell surface appropriately;
FT                   dbSNP:rs1085307428)"
FT                   /evidence="ECO:0000269|PubMed:14684682"
FT                   /id="VAR_026816"
FT   MUTAGEN         74..76
FT                   /note="REL->DFQ: Affinity for BMP9 decreased by 200-fold."
FT                   /evidence="ECO:0000269|PubMed:22799562"
FT   CONFLICT        172
FT                   /note="S -> T (in Ref. 1; CAA80255)"
FT                   /evidence="ECO:0000305"
FT   HELIX           26..28
FT                   /evidence="ECO:0007829|PDB:2LCR"
FT   STRAND          32..35
FT                   /evidence="ECO:0007829|PDB:6SF3"
FT   STRAND          42..56
FT                   /evidence="ECO:0007829|PDB:6SF3"
FT   STRAND          59..61
FT                   /evidence="ECO:0007829|PDB:6SF1"
FT   STRAND          64..72
FT                   /evidence="ECO:0007829|PDB:6SF3"
FT   HELIX           74..78
FT                   /evidence="ECO:0007829|PDB:6SF3"
FT   STRAND          83..90
FT                   /evidence="ECO:0007829|PDB:6SF3"
FT   TURN            93..96
FT                   /evidence="ECO:0007829|PDB:6SF3"
FT   HELIX           198..201
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          203..211
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          214..221
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          224..231
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           233..235
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           236..248
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          259..265
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          267..269
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          272..278
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           285..291
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           296..314
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          325..327
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          335..338
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          344..346
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          353..355
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          357..359
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           373..375
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           378..381
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           390..410
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   TURN            424..428
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           435..442
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   STRAND          455..459
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   TURN            460..462
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           463..469
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           476..478
FT                   /evidence="ECO:0007829|PDB:3MY0"
FT   HELIX           482..491
FT                   /evidence="ECO:0007829|PDB:3MY0"
SQ   SEQUENCE   503 AA;  56124 MW;  074522AA802325DD CRC64;
     MTLGSPRKGL LMLLMALVTQ GDPVKPSRGP LVTCTCESPH CKGPTCRGAW CTVVLVREEG
     RHPQEHRGCG NLHRELCRGR PTEFVNHYCC DSHLCNHNVS LVLEATQPPS EQPGTDGQLA
     LILGPVLALL ALVALGVLGL WHVRRRQEKQ RGLHSELGES SLILKASEQG DSMLGDLLDS
     DCTTGSGSGL PFLVQRTVAR QVALVECVGK GRYGEVWRGL WHGESVAVKI FSSRDEQSWF
     RETEIYNTVL LRHDNILGFI ASDMTSRNSS TQLWLITHYH EHGSLYDFLQ RQTLEPHLAL
     RLAVSAACGL AHLHVEIFGT QGKPAIAHRD FKSRNVLVKS NLQCCIADLG LAVMHSQGSD
     YLDIGNNPRV GTKRYMAPEV LDEQIRTDCF ESYKWTDIWA FGLVLWEIAR RTIVNGIVED
     YRPPFYDVVP NDPSFEDMKK VVCVDQQTPT IPNRLAADPV LSGLAQMMRE CWYPNPSARL
     TALRIKKTLQ KISNSPEKPK VIQ
//
